I rate Cognition Therapeutics a "Strong Buy" due to FDA alignment on two pivotal phase 3 trials zervimesine in mild-to-moderate Alzheimer's patients with low p-tau217; Successful results means NDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback